Menu
Menu
J Clin Aesthet Dermatol. 2024;17(1):24–27. by Suparuj Lueangarun, MD, MSc, and Therdpong Tempark, MD Dr. Lueangarun is with the Department of Anti-Aging and Regenerative Medicine Medicine, College of Integrative Medicine
J Clin Aesthet Dermatol. 2023;16(3 Suppl 1):S29–S33 by Rohan R. Shah, BA; Zaeem Nazar, MD; Alyssa Swearingen, BS; Nadia Waqas, MD; Shawana Sharif, MD; and Babar Rao, MD Mr. Shah
J Clin Aesthet Dermatol. 2022;15(12):19–21. by Grace S. Ahn, MD*; Aislyn Oulee, BS*; Shahin Shahsavari, BS; Amylee Martin, MD; and Jashin J. Wu, MD *Dr. Ahn and Ms. Oulee share
J Clin Aesthet Dermatol. 2021;14(2):42–43. by Noureddine Litaiem, MD; Olfa Charfi, MD; Takwa Bacha, MD; and Faten Zeglaoui, MD, PhD All authors are with the Department of Dermatology at Charles
J Clin Aesthet Dermatol. 2021;14(2):26–33. by Brianna De Souza, MD; Andrea Tovar-Garza, MD; Laura N. Uwakwe, MD; and Amy McMichael, MD All authors are with the Department of Dermatology
J Clin Aesthet Dermatol. 2020;13(4):45–50 by Pooja Bains, MBBS, MD and Simplepreet Kaur, MBBS, MD Drs. Bains and Kaur are with the Department of Dermatology, Venereology, and Leprosy at Sri
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis,
